A fatal CRISPR-based gene-editing case in China has raised fresh questions about ethics and oversight after a young patient died following an experimental, brain-directed base-editing treatment, according to Science. The report details how the therapy used viral delivery of instructions for a custom base editor, with investigators pointing to unusual risk arrangements and oversight gaps. Separately, the same week saw heightened regulatory focus on peptide compounding (see other cluster), underscoring how quickly translational innovation is colliding with safety governance. While CRISPR remains a central platform for in vivo gene medicine, the China case adds pressure on trial design, data transparency, and adverse event handling expectations for early-stage neurological programs.